ARC
ANIK icon

Absolute Return Capital’s Anika Therapeutics ANIK Stock Holding History

Absolute Return Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-69,135
Closed -$3.2M – 625
2014
Q2 		$3.2M Buy
+69,135
New +$3.07M 0.04% 469

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Absolute Return Capital's ANIK Position: Q3 2014 in Review

Absolute Return Capital sold out of Anika Therapeutics (ANIK) in Q3 2014, closing a stake of 69,135 shares — an estimated $3.2M sold.

Absolute Return Capital first reported a position in ANIK in Q2 2014 and held it in 1 quarter. The position peaked at $3.2M in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

  • Absolute Return Capital reported no remaining Anika Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 69,135 Anika Therapeutics shares in Q3 2014, an estimated $3.2M.
  • Absolute Return Capital first reported a position in Anika Therapeutics in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Anika Therapeutics position peaked at $3.2M in Q2 2014.
  • 153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.